Skip to main content

Table 2 Mean BP and proportion of participants reaching BP goal (<130/80 mm Hg) at weeks 12 and 52/ET

From: Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study

Time point Diabetes CKD Chronic CVD
Week 12
n 333 93 191
OM 40/AML 5/HCTZ 12.5 mg* 138.9/81.2 (17.4/9.6) 135.0/76.5 (20.6/10.9) 137.7/81.4 (15.7/10.3)
% to goal 22 40 25
Week 52/ET
n 62 29 56
OM 40/AML 5/HCTZ 12.5 mg 121.4/74.9 (14.5/8.8) 118.4/70.9 (12.6/7.9) 127.1/77.1 (18.8/12.4)
% to goal 65 79 54
n 34 13 29
OM 40/AML 5/HCTZ 25 mg 129.5/77.2 (15.6/9.9) 126.5/72.4 (22.5/10.5) 134.2/78.0 (17.0/11.6)
% to goal 38 54 35
n 40 14 20
OM 40/AML 10/HCTZ 12.5 mg 128.8/77.0 (11.6/8.5) 122.3/70.9 (15.6/8.1) 132.9/77.6 (11.1/8.5)
% to goal 50 43 20
n 197 36 86
OM 40/AML 10/HCTZ 25 mg 136.7/79.7 (15.2/9.7) 134.0/75.0 (17.7/10.3) 138.4/82.3 (16.2/10.6)
% to goal 24 31 27
  1. BP data are mean (SD), mm Hg.
  2. *Week 12 data are from the end of the double-blind treatment period before all participants were switched to OM 40/AML 5/HCTZ 12.5 mg at the beginning of the open-label extension period.
  3. AML, amlodipine; BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; ET, early termination; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SD, standard deviation.